Solid Tumor Completed Phase 1 Trials for Pazopanib (DB06589)

Also known as: Cancer - Solid Tumors / Solid Tumour / Solid Tumours / Tumor, Solid / Solid Neoplasms / Solid tumour/cancer / Solid Cancers / Cancer: Solid Tumors / Neoplasms, Solid Tumor / Cancer, Solid Tumor / Tumors, Solid / Solid Tumor Cancer / Solid Tumors or Cancers / Solid Tumors / Solid Neoplasm / Cancer (Solid Tumors) / Solid Tumor Neoplasms / Solid Tumor Cancers / Solid Cancer / Neoplasm / Neoplasm (morphologic abnormality) / Neoplasms of unspecified behavior / Neoplasms NOS / Neoplasms NOS (disorder) / [M]Neoplasms NOS (morphologic abnormality) / Neoplasm (NOS) / Tumor / Neoplasm NOS / Tumour / Tumour NOS / Neoplasms / Tumour, NOS / Tumor NOS / Neoplasm, NOS / Tumor, NOS / Neoplasms benign, malignant and unspecified (incl cysts and polyps)

IndicationStatusPhase
DBCOND0030180 (Solid Tumor)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00732420
Open-label Study of Topotecan and Pazopanib in Advanced Solid TumorsScreening
NCT01468922
Pazopanib and ARQ 197 for Advanced Solid TumorsTreatment
NCT01184326
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial CancerTreatment
NCT01543763
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid TumorsTreatment
NCT01202032
Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid TumorsTreatment
NCT02009449
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsTreatment
NCT01438554
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and CholangiocarcinomaOther
NCT02303028
Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid TumoursTreatment
NCT01485042
Dose Escalation Study of Pazopanib Plus TH-302Other
NCT01165385
Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid TumorsTreatment
NCT01430572
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss PatientsTreatment
NCT01072890
Temsirolimus and Pazopanib in Patients With Advanced Solid TumorsTreatment
NCT00929903
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to TreatmentTreatment